Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary 
Medicus Pharma submits FDA plan to develop microneedle-based treatment for skin cancer in horses
Medicus Pharma (NASDAQ:MDCX) said on Monday it has submitted a comprehensive product development plan to the US Food and Drug Administration (FDA) to advance its investigational treatment for external squamous cell carcinoma (SCC) in horses. The plan was submitted under the company's existing Investigational New Animal Drug file and follows the FDA's Minor Use in Major Species designation, which Medicus received in December 2024 for its dissolvable Doxorubicin-containing microneedle array (D-MNA).
Medicus Pharma appoints KPMG as new auditor, expands global clinical programs
Medicus Pharma (NASDAQ:MDCX) said it has appointed KPMG as its independent registered public accounting firm for the 2025 fiscal year, replacing EisnerAmper following a review process led by the company's audit committee and approved by its board. The transition, announced on June 4, comes as the clinical-stage biotech company ramps up its global operations and research programs.
Medicus Pharma unveils pricing of $7M public offering
Medicus Pharma (NASDAQ:MDCX) has announced the pricing of its $7 million public offering of 2.26 million shares on a “best-efforts” basis at $3.10 per unit. Each unit includes one share and one warrant to purchase a share at an exercise price of $3.10, with the warrants expiring five years from the date of issuance and not trading on any securities exchange.
Medicus Pharma begins UAE cancer trial expansion – ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's newly announced regulatory approval to expand its Phase 2 trial into the United Arab Emirates. The study is focused on a noninvasive therapy for basal cell carcinoma (BCC), the most common form of cancer globally.
Medicus Pharma gets UAE approval for Phase 2 study for skin cancer therapy
Medicus Pharma (NASDAQ:MDCX) has received regulatory approval from the UAE Department of Health to begin a Phase 2 clinical trial evaluating its non-invasive therapy for basal cell carcinoma (BCC) of the skin. The study, designated SKNJCT-004, will enroll up to 36 patients across four medical centers in the UAE.
Medicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatment
Medicus Pharma (NASDAQ:MDCX) announced that it has entered into a binding letter of intent to acquire Antev, a clinical-stage biotechnology firm developing a first-in-market product Teverelix for acute urinary retention (AUR) and high cardiovascular risk prostate cancer. Teverelix, a next-generation GnRH antagonist, targets the prevention of recurrent AUR in males aged 45 years and older with benign prostate hyperplasia.
Medicus Pharma expands basal cell carcinoma study after encouraging early data
Medicus Pharma (NASDAQ:MDCX) said it has received approval from an Institutional Review Board (IRB) to increase the number of participants in its ongoing Phase 2 clinical trial of a novel non-invasive treatment for basal cell carcinoma (BCC), the most common form of skin cancer. The company will raise the trial's enrollment target to 90 patients from 60 and expand the study beyond the current nine clinical sites in the United States to additional US locations and two in Europe.
Medicus Pharma CEO discusses latest skin cancer trial results - ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the latest progress in the company's ongoing clinical trials for its innovative skin cancer treatment. The company is developing a non-invasive microneedle-based therapy designed to treat basal cell carcinoma by delivering doxorubicin directly to the lesion site.
Medicus Pharma unveils pricing of financing to advance skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) has announced the pricing of its Tier II Regulation A offering, aiming to raise approximately $4.2 million through the sale of 1.49 million units at $2.80 per unit. Each unit includes one common share and one warrant, with the warrants exercisable at $2.80 per share for a five-year period.
Medicus Pharma's Phase 2 skin cancer trial hits key milestone - ICYMI
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) CEO Dr Raza Bokhari talked with Proactive about the company's ongoing Phase 2 clinical study for its lead asset, SKNJCT. This novel, noninvasive treatment is designed to deliver doxorubicin directly to basal cell carcinoma lesions.
Medicus Pharma expects interim data from Phase 2 skin cancer trial by quarter-end
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) has announced progress in its Phase 2 clinical study SKNJCT-003, which is evaluating its investigational drug D-MNA in basal cell carcinoma (BCC). The company said that the trial, currently underway at nine clinical sites in the United States, has now randomized more than 50% of the 60 patients expected to be enrolled.
Medicus Pharma announces equity deal, shifts focus to Nasdaq
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that it has entered into a Standby Equity Purchase Agreement with YA II PN, an investment fund managed by Yorkville Advisors Global, to sell up to US$15 million of its shares over 36 months. The investor's purchase of shares under the agreement is subject to SEC approval of a resale registration statement.
